Harrow, Inc.
Description
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
About
CEO
Mr. Mark L. Baum J.D.
Employees
315
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNMS
Address
102 Woodmont Boulevard, Nashville, TN 37205, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 5, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Mar 17, 2025 | — | — | — | — |
| Nov 14, 2024 | -0.05 | -0.12 | -0.07 | 140.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 2 |
| Average estimate | — | 0.14 | — | 0.89 |
| Low estimate | — | 0.13 | — | 0.78 |
| High estimate | — | 0.15 | — | 0.99 |
| Last year EPS | — | -0.28 | — | -0.41 |
[stock_revenue_estimate]
Growth estimates
Current qtr
130.000%
Next qtr. (Mar 2025)
141.070%
Current year
-25.710%
Next year (Dec 2025)
287.500%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M |
| Cost of revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M |
| Gross profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M |
| Operating expense | |||||
| Research & development | 6.65M | 3.05M | 11.08M | 2.41M | 2.08M |
| Selling general and admin | 83.09M | 58.24M | 41.32M | 31.25M | 33.09M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 811,000 | 1.92M | 1.86M | 748,000 | -755,000 |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 21.32M | 7.24M | — | — | — |
| Other income expense | -3.20M | -8.69M | -14.30M | -1.93M | 3.14M |
| Pretax income | -23.71M | -14.01M | -17.87M | -3.42M | -117,000 |
| Tax provision | 701,000 | 75,000 | 133,000 | 4,000 | 8,000 |
| Net income | -24.41M | -14.09M | -18.01M | -3.42M | -125,000 |
| Basic EPS | -0.75 | -0.51 | -0.69 | -0.13 | 0.01 |
| Diluted EPS | -0.75 | -0.51 | -0.69 | -0.13 | 0.01 |
| Basic average shares | 32.62M | 27.62M | 26.78M | 25.82M | 25.32M |
| Diluted average shares | 32.62M | 27.62M | 26.78M | 25.82M | 25.32M |
| EBITDA | 12.71M | -5.45M | 13.42M | 599,000 | 2.17M |
| Net income from continuing op. | -24.41M | -14.09M | -18.01M | -3.42M | -125,000 |
| Minority interests | — | — | — | 62,000 | 293,000 |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 312.16M | 157.38M | 98.33M | 57.47M | 59.09M |
| Current assets | |||||
| Cash | 74.09M | 96.27M | 42.17M | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 74.09M | 96.27M | 42.17M | 4.10M | 4.75M |
| Other short term investments | 8.68M | 5.59M | 8.50M | 28.46M | 25.20M |
| Accounts receivable | 36.26M | 6.25M | 4.47M | 2.66M | 2.01M |
| Other receivables | — | — | — | — | — |
| Inventory | 10.87M | 6.54M | 4.22M | 3.96M | 3.30M |
| Prepaid assets | 7.20M | 3.35M | 1.17M | 751,000 | 586,000 |
| Restricted cash | — | — | — | 200,000 | 200,000 |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 1.75M | 118,000 | 92,000 | — | — |
| Non current assets | |||||
| Properties | 4.56M | 4.26M | 4.06M | 3.43M | 3.16M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.26M | 1.84M | 1.22M | 1.11M | 2.10M |
| Construction in progress | — | — | — | — | — |
| Leases | 6.77M | 6.45M | 5.70M | 5.72M | 5.51M |
| Accumulated depreciation | -10.07M | -9.06M | -7.83M | -6.39M | -5.39M |
| Goodwill | 162.71M | 26.50M | 17.79M | 3.19M | 3.00M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 162.04M | 25.84M | 17.13M | 2.52M | 2.34M |
| Investments and advances | — | — | 11.13M | 2.97M | 8.44M |
| Other non current assets | — | 1.95M | — | — | — |
| Total liabilities | 241.75M | 130.14M | 87.40M | 30.65M | 31.67M |
| Current liabilities | |||||
| Accounts payable | 21.42M | 6.44M | 5.17M | 3.93M | 7.70M |
| Accrued expenses | 27.04M | 11.36M | 4.25M | 2.32M | 2.12M |
| Short term debt | 806,000 | 723,000 | 280,000 | 4.49M | 2.41M |
| Deferred revenue | 75,000 | 113,000 | 16,000 | 66,000 | 57,000 |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 189.70M | 111.51M | 77.68M | 19.05M | 18.58M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 35,000 | 30,000 | 27,000 | 26,000 | 26,000 |
| Retained earnings | -133.90M | -109.49M | -95.41M | -77.40M | -74.04M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 70.41M | 27.24M | 10.93M | 26.83M | 27.42M |
| Additional paid in capital | 204.64M | 137.06M | 106.67M | 104.56M | 101.73M |
| Treasury stock | — | — | — | — | — |
| Minority interest | -355,000 | -355,000 | -355,000 | -355,000 | -293,000 |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -125,000 | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953,936 | -2.53M | -4.55M | -3.30M | -4.28M | -13,642 | -46,206 |
| Depreciation | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610,000 | 85,000 | 5,659 | 2,944 | 338 | 1,056 | 1,056 | 704 | 201,252 | — | — |
| Deferred Taxes | — | — | — | — | — | — | -935,000 | -111,000 | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 15.70M | 7.97M | 5.75M | 2.78M | 2.02M | 2.64M | 2.94M | 3.67M | 3.44M | 2.62M | 3.13M | 2.16M | 192,153 | 680,195 | 509,505 | 562,442 | 184,522 | — | — |
| Other Non-Cash Items | 4.10M | 782,000 | 677,000 | 898,000 | 512,000 | 613,000 | 978,000 | 1.09M | 380,000 | 2.61M | 293,138 | 24,658 | 329,142 | 55,479 | 538,553 | 904,150 | 1.65M | — | 1,200 |
| Accounts Receivable | -30.34M | -1.86M | -1.83M | -866,000 | -95,000 | -384,000 | 1.39M | -2.08M | -360,000 | -23,000 | — | — | — | — | — | — | — | — | — |
| Accounts Payable | 31.80M | 933,000 | 1.73M | -4.66M | 1.34M | 2.37M | 346,000 | 1.52M | 1.03M | 345,000 | -239,800 | 231,435 | 144,980 | -607,382 | 124,624 | -139,951 | 612,562 | — | — |
| Other Assets & Liabilities | -4.36M | -2.23M | -305,000 | -652,000 | -2.33M | 505,000 | -883,000 | -403,000 | -251,000 | -181,633 | — | -100,000 | 20,000 | 160,000 | — | — | 53,901 | -1,070 | 4,950 |
| Operating Cash Flow | 4.81M | -4.82M | -9.60M | -3.18M | 3.99M | 22.20M | -6.38M | -14.00M | -11.05M | -4.66M | -4.45M | -3.07M | -267,323 | -2.24M | -3.38M | -1.98M | -1.58M | -14,712 | -40,056 |
| Investing Activities | |||||||||||||||||||
| Capital Expenditures | -1.46M | -2.57M | -1.79M | -862,000 | -1.47M | -1.77M | -772,000 | -6.89M | -995,000 | -174,000 | -20,003 | -15,492 | — | — | — | -3,154 | — | — | — |
| Net Intangibles | -151.09M | -5.18M | -14.13M | -132,000 | -369,000 | -435,000 | -302,000 | -252,000 | -185,000 | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | 9.83M | — | — | — | — | — | -3.43M | -636,000 | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | -50,000 | — | -100,000 | -50,000 | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | 9.83M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -1.46M | 3.43M | 17.87M | -849,000 | -1.46M | -1.76M | -659,000 | -7.04M | -4.95M | -910,000 | -70,003 | -15,492 | — | — | — | -3,154 | — | — | — |
| Financing Activities | |||||||||||||||||||
| Long-Term Debt Issuance | 134.39M | 31.74M | 71.07M | 2.97M | — | — | 15.52M | 4.71M | 9.27M | — | — | — | — | 1.00M | — | — | — | — | — |
| Long-Term Debt Payments | -59.75M | -18,000 | -7,000 | -8,000 | -1.49M | -691,000 | -14.63M | -267,000 | -25,000 | -10,000 | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -13.01M | -876,000 | -19.19M | -1.53M | -282,000 | -53,000 | -206,000 | -195,000 | -135,000 | -10,431 | — | 50,000 | -254,142 | — | — | — | 105,907 | — | — |
| Financing Cash Flow | 126.15M | 53.50M | 51.41M | 1.43M | -1.78M | -102,000 | 4.75M | 24.76M | 9.51M | 588,569 | 10.05M | 11.81M | 145,858 | 1.00M | 49,500 | 3.94M | 5.47M | — | 80,000 |
| Other Cash Details | |||||||||||||||||||
| End Cash Position | 74.09M | 96.27M | 42.17M | 4.30M | 4.95M | 6.84M | 4.22M | 8.85M | 2.69M | 8.21M | 15.58M | 10.04M | 146,160 | 291,462 | 1.59M | 5.11M | 3.71M | 16,982 | 39,944 |
| Income Tax Paid | — | 75,000 | 11,000 | 4,000 | 17,000 | 4,000 | 9,000 | 9,000 | 1,000 | 1,000 | 1,600 | 1,600 | 2,400 | — | — | — | — | — | — |
| Interest Paid | 18.89M | 6.48M | 4.82M | 1.79M | 1.97M | 2.10M | 1.54M | 1.37M | 637,000 | 4,000 | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -148.71M | -6.07M | -23.43M | -2.09M | -887,000 | -1.52M | -9.88M | -18.35M | -12.32M | -7.23M | -4.46M | -1.92M | -291,160 | -2.30M | -3.57M | -2.54M | -1.76M | -22,962 | -40,056 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 994,805 | 30.73M | 2.79% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 857,629 | 26.49M | 2.41% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 464,889 | 14.36M | 1.31% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 312,109 | 9.64M | 0.88% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 274,009 | 8.46M | 0.77% |
| College Retirement Equities Fund-Stock Account | Sep 30, 2024 | 252,020 | 7.78M | 0.71% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 168,506 | 5.21M | 0.47% |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | Nov 30, 2024 | 148,383 | 4.58M | 0.42% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 143,852 | 4.44M | 0.40% |
| FundVantage Tr-Private Capital Management Value Fund | Oct 31, 2024 | 122,430 | 3.78M | 0.34% |
Article
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient support services hub, Harrow Cares ensures seamless enrollment, rapid.
Jan 27, 2025
Article
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophtha.
Jan 7, 2025
Article
Those Derisked Baby Bonds Of Harrow, Inc.
Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addressing supply chain issues and justified price hikes, ensuring strong future demand.
Jan 3, 2025
